nach oben

Erschienen in:

01.02.2010

Estrogen-Induced Aurora Kinase-A (AURKA) Gene Expression is Activated by GATA-3 in Estrogen Receptor-Positive Breast Cancer Cells

verfasst von: Shoulei Jiang, Hiroshi Katayama, Jin Wang, Sara Antonia Li, Yan Hong, Laszlo Radvanyi, Jonathan J. Li, Subrata Sen

Erschienen in: Discover Oncology | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Aurora-A is a proto-oncogenic mitotic kinase that is frequently overexpressed in human epithelial malignancies including in breast and ovarian cancers. The mechanism of transcriptional upregulation of Aurora-A in human breast cancer is not yet elucidated. We report herein that Aurora-A transcription is positively regulated by GATA-3 in response to estrogen in estrogen receptor α (ERα)-positive cells. Transient expression of aurora-A promoter deletion mutants in luciferase constructs identified a GATA binding sequence motif as a functional regulatory element in ERα-positive breast cancer cells. Electrophoretic mobility shift assay identified the binding of regulatory proteins to the GATA element. Anti-GATA-3 antibody generated a supershifted complex. Recruitment of GATA-3 to the aurora-A promoter was verified by chromatin immunoprecipitation analysis with GATA-3 antibody. Ectopic expression of GATA-3 resulted in elevated expression of Aurora-A in both ERα-positive and negative cells while siRNA-mediated silencing led to downregulation of endogenous Aurora-A in ERα-positive cells. Estrogen treatment of ERα-positive cells induced increased Aurora-A expression with enhanced recruitment of GATA-3 to the aurora-A promoter. Finally, in the ACI rat model of estrogen-induced breast cancer, known to be associated with elevated Aurora-A expression, we observed increased expression of GATA-3 in preinvasive and invasive mammary epithelial cells exposed to prolonged estrogen treatment and in developing breast tumors. These results demonstrate a direct positive role of estrogen in regulating Aurora-A expression through activation of the ERα-GATA-3 signaling cascade and suggest that this pathway may be critical in the origin of estrogen-stimulated sporadic breast cancer.

Marumoto T, Zhang D, Saya H (2005) Aurora-A—a guardian of poles. Nat Rev Cancer 5:42–50CrossRefPubMed

Sen S, Zhou H, White RA (1997) A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogenes 14:2195–2200CrossRef

Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C et al (1998) A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 17:3052–3065CrossRefPubMed

Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, Brinkley BR, Sen S (1998) Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20:189–193CrossRefPubMed

Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, Shelley SA, Fiorica JV, Nicosia SV, Cheng JQ (2003) Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res 9:1420–1426PubMed

Hoque A, Carter J, Xia W, Hung MC, Sahin AA, Sen S, Lippman SM (2003) Loss of aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast. Cancer Epidemiol Biomarkers Prev 12:1518–1522PubMed

Katayama H, Brinkley WR, Sen S (2003) The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 22:451–464CrossRefPubMed

Engelbert D, Schnerch D, Baumgarten A, Wäsch R (2008) The ubiquitin ligase APC(Cdh1) is required to maintain genome integrity in primary human cells. Oncogenes 27:907–917CrossRef

Tanaka M, Ueda A, Kanamori H, Ideguchi H, Yang J, Kitajima S, Ishigatsubo Y (2002) Cell-cycle-dependent regulation of human aurora A transcription is mediated by periodic repression of E4TF1. J Biol Chem 277:10719–10726CrossRefPubMed

10.

Udayakumar TS, Belakavadi M, Choi KH, Pandey PK, Fondell JD (2006) Regulation of Aurora-A kinase gene expression via GABP recruitment of TRAP220/MED1. J Biol Chem 281:14691–14699CrossRefPubMed

11.

He L, Yang H, Ma Y, Pledger WJ, Cress WD, Cheng JQ (2008) Identification of Aurora-A as a direct target of E2F3 during G2/M cell cycle progression. J Biol Chem 283:31012–31020CrossRefPubMed

12.

Hung LY, Tseng JT, Lee YC, Xia W, Wang YN, Wu ML, Chuang YH, Lai CH, Chang WC (2008) Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression. Nucleic Acids Res 36:4337–4351CrossRefPubMed

13.

Wakahara K, Ohno T, Kimura M, Masuda T, Nozawa S, Dohjima T, Yamamoto T, Nagano A, Kawai G, Matsuhashi A et al (2008) EWS-Fli1 up-regulates expression of the Aurora A and Aurora B kinases. Mol Cancer Res 6:1937–1945CrossRefPubMed

14.

Li JJ, Weroha SJ, Lingle WL, Papa D, Salisbury JL, Li SA (2004) Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats. Proc Natl Acad Sci USA 101:18123–18128CrossRefPubMed

15.

Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG, Gustafsson JA (2006) International union of pharmacology. LXIV. Estrogen receptors. Pharmacol Rev 58:773–781CrossRefPubMed

16.

Doisneau-Sixou SF, Sergio CM, Carroll JS, Hui R, Musgrove EA, Sutherland RL (2003) Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr Relat Cancer 10:179–186CrossRefPubMed

17.

Eeckhoute J, Keeton EK, Lupien M, Krum SA, Carroll JS, Brown M (2007) Positive cross-regulatory loop ties GATA-3 to estrogen receptor alpha expression in breast cancer. Cancer Res 67:6477–6483CrossRefPubMed

18.

Fang SH, Chen Y, Weigel RJ (2008) GATA-3 as a Marker of Hormone Response in Breast Cancer. J Surg Res 67(13):6477–6483. doi:10.1016/j.jss.2008.07.015

19.

Lee HH, Zhu Y, Govindasamy KM, Gopalan G (2008) Downregulation of Aurora-A overrides estrogen-mediated growth and chemoresistance in breast cancer cells. Endocr Relat Cancer 15:765–775CrossRefPubMed

20.

Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344:276–285CrossRefPubMed

21.

Ikeda K, Inoue S (2004) Estrogen receptors and their downstream targets in cancer. Arch Histol Cytol 67:435–442CrossRefPubMed

22.

Sharma P, Kimler BF, Warner C, Metheny T, Xue Q, Zalles CM, Fabian CJ (2006) Estrogen receptor expression in benign breast ductal cells obtained from random periareolar fine needle aspiration correlates with menopausal status and cytomorphology index score. Breast Cancer Res Treat 100:71–76CrossRefPubMed

23.

Li SA, Weroha SJ, Tawfik O, Li JJ (2002) Prevention of solely estrogen-induced mammary tumors in female aci rats by tamoxifen: evidence for estrogen receptor mediation. J Endocrinol 175:297–305CrossRefPubMed

24.

Mabuchi S, Ohmichi M, Kimura A, Nishio Y, Arimoto-Ishida E, Yada-Hashimoto N, Tasaka K, Murata Y (2004) Estrogen inhibits paclitaxel-induced apoptosis via the phosphorylation of apoptosis signal-regulating kinase 1 in human ovarian cancer cell lines. Endocrinology 145:49–58CrossRefPubMed

25.

Anand S, Penrhyn-Lowe S, Venkitaraman AR (2003) AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3:51–62CrossRefPubMed

26.

Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, Fujii S, Arlinghaus RB, Czerniak BA, Sen S (2004) Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 36:55–62CrossRefPubMed

27.

Ouchi M, Fujiuchi N, Sasai K, Katayama H, Minamishima YA, Ongusaha PP, Deng C, Sen S, Lee SW, Ouchi T (2004) BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. J Biol Chem 279:19643–19648CrossRefPubMed

28.

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752CrossRefPubMed

29.

Lacroix M, Leclercq G (2004) About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-alpha gene (ESR1) in breast cancer. Mol Cell Endocrinol 219:1–7CrossRefPubMed

30.

Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z (2006) GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127:1041–1055CrossRefPubMed

31.

Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC, Hartley L, Robb L, Grosveld FG, van der Wees J et al (2007) Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat Cell Biol 9:201–209CrossRefPubMed

32.

Bertucci F, Houlgatte R, Benziane A, Granjeaud S, Adélaïde J, Tagett R, Loriod B, Jacquemier J, Viens P, Jordan B et al (2000) Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum Mol Genet 9:2981–2991CrossRefPubMed

33.

Mallepell S, Krust A, Chambon P, Brisken C (2006) Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland. Proc Natl Acad Sci USA 103:2196–2201CrossRefPubMed

34.

Kouros-Mehr H, Kim JW, Bechis SK, Werb Z (2008) GATA-3 and the regulation of the mammary luminal cell fate. Curr Opin Cell Biol 20:164–170CrossRefPubMed

35.

Manuylov NL, Smagulova FO, Tevosian SG (2007) Fog2 excision in mice leads to premature mammary gland involution and reduced Esr1 gene expression. Oncogenes 26:5204–5213CrossRef

36.

Lingle WL, Barrett SL, Negron VC, D'Assoro AB, Boeneman K, Liu W, Whitehead CM, Reynolds C, Salisbury JL (2002) Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci USA 99:1978–1983CrossRefPubMed

37.

Goepfert TM, Adigun YE, Zhong L, Gay J, Medina D, Brinkley WR (2002) Centrosome amplification and overexpression of aurora A are early events in rat mammary carcinogenesis. Cancer Res 62:4115–4122PubMed

38.

Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual, 2nd edn. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

39.

Katayama H, Sasai K, Czerniak BA, Carter JL, Sen S (2007) Aurora-A kinase phosphorylation of Aurora-A kinase interacting protein (AIP) and stabilization of the enzyme-substrate complex. J Cell Biochem 102:1318–1331CrossRefPubMed

40.

Peng Y, Jahroudi N (2003) The NFY transcription factor inhibits von Willebrand factor promoter activation in non-endothelial cells through recruitment of histone deacetylases. J Biol Chem 278:8385–8394CrossRefPubMed

Titel: Estrogen-Induced Aurora Kinase-A (AURKA) Gene Expression is Activated by GATA-3 in Estrogen Receptor-Positive Breast Cancer Cells
verfasst von: Shoulei Jiang
Hiroshi Katayama
Jin Wang
Sara Antonia Li
Yan Hong
Laszlo Radvanyi
Jonathan J. Li
Subrata Sen
Publikationsdatum: 01.02.2010
Verlag: Springer-Verlag
Erschienen in: Discover Oncology / Ausgabe 1/2010
Print ISSN: 1868-8497
Elektronische ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-010-0006-x

Springer Medizin

Estrogen-Induced Aurora Kinase-A (AURKA) Gene Expression is Activated by GATA-3 in Estrogen Receptor-Positive Breast Cancer Cells

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

Quantitative Immunohistochemical Analysis and Prognostic Significance of TRPS-1, a New GATA Transcription Factor Family Member, in Breast Cancer

Circulating Sex Steroids and Breast Cancer Risk in Premenopausal Women

Specific Overexpression of Cyclin E·CDK2 in Early Preinvasive and Primary Breast Tumors in Female ACI Rats Induced by Estrogen

Letter from the Editor-in-Chief

Mouse Prostate Cancer Cell Lines Established from Primary and Postcastration Recurrent Tumors

Trends in Distant-Stage Breast, Colorectal, and Prostate Cancer Incidence Rates from 1992 to 2004: Potential Influences of Screening and Hormonal Factors

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie